Genedata data analysis solution enables a modern infrastructure that supports Evotec’s complex screening experiments for collaborative drug discovery research
June 28, 2016
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Evotec, one of the world’s leading contract research organizations, has selected Genedata Screener® as a data management platform solution for its drug discovery projects. Originally deployed for High Content Screening (HCS), Evotec now also licenses Genedata Screener for its High Throughput Screening (HTS) operations. This capability further strengthens Evotec’s support of drug discovery research projects with global pharmaceutical, biotechnology, and academic partners.
Leading CROs and More than 50% of the World’s Top Pharmas Run Genedata Screener
Genedata Screener is relied on by many innovative contract research organizations (CROs) and is used by more than 50% of the world’s leading pharmaceutical companies. It enables CROs to efficiently serve their customers with quick yet thorough data analysis, ensuring scientists deliver well-curated results. While Evotec uses Screener for HCS and HTS, the platform also supports a broad range of modern screening technologies including: Surface Plasmon Resonance; Thermal Shift Analysis; Compound Combinations; HT-Flow; Ion Channel; and Profiling.
“Genedata Screener is one of the standard screening platforms for many of our pharmaceutical customers,” said Dr. Dirk Ullmann, EVP Lead Discovery of Evotec. “Standardizing result generation and quality control, Genedata Screener is key to our customer collaborations because it allows everyone to quickly understand the results and result quality. It enables our scientists to deliver results quickly and easily to our customers.”
One Platform for Full HTS and HCS Analysis
Genedata Screener for both HCS and HTS provides stringent quality assurance, transparent hit identification, and interactively curates any process errors. It enables scientists to easily understand what causes artifacts or quickly identify new phenotypes. And, it can quickly pull original HCS images, dozens out of millions, in a full HCS campaign. These efficiencies are further complemented by the Genedata Screener infrastructure, which reduces costs and maintenance as it hosts full HTS and HCS data analysis in one system, scales to all throughputs, and adapts to widely-used assay formats.
“Genedata Screener has become the software of choice for screening data analysis in pharma and bio-pharma industries,” noted Dr. Othmar Pfannes, CEO of Genedata. “Therefore, we’re seeing increased Screener adoption by leading CROs, such as Evotec, who see quantifiable value in using the same data analysis methodology used by their customers. Genedata is committed to increasing that value by investing in our software so that it continually keeps pace with new business concepts, technologies and workflows as they arise.”
About Evotec AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer’s disease, with MedImmune and Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and with Second Genome in the field of inflammatory diseases. For additional information please go to www.evotec.com.